RS50969B - Jedinjenja indolina - Google Patents
Jedinjenja indolinaInfo
- Publication number
- RS50969B RS50969B RSP-2009/0244A RSP20090244A RS50969B RS 50969 B RS50969 B RS 50969B RS P20090244 A RSP20090244 A RS P20090244A RS 50969 B RS50969 B RS 50969B
- Authority
- RS
- Serbia
- Prior art keywords
- alkyl
- halo
- cycloalkyl
- alkoxy
- cor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Jedinjenje sulfonilindolina, naznačeno time, stoje odabrano od:i) jedinjenja formulegde- R1 je atom vodonika, halogena, C1-C4 alkil grupa, C1-C4 alkoksi grupa, trifluorometil grupa ili potpuno ili delimično halogenizovana metoksi grupa,- R2 je atom vodonika, halogena, C1-C4 alkil grupa ili trifluorometil grupa,- R3 je atom vodonika, halogena, C1-C4 alkil grupa ili trifluorometil grupa, pod uslovom da R1, R2 i R3 nisu istovremeno atom vodonika,- R4 je atom vodonika ili C1-C4 alkoksi grupa,- Y je lineanarna ili razgranata C1-C8 alkilen grupa po izboru supstituisana trifluorometil grupom ili fenil prstenom, ili sadrži ciklopropil ili cikloheksil grupu, ili je -(CH2)n-W- grupa,- W je atom kiseonika, -NH- grupa ili atom sumpora,- n je 2, 3 ili 4,- Z je po izboru delimično halogenizovana C1-C4 alkil grupa, trifluorometil, -CORa, -CH2-N(R)2, ili aromatičan, heteroaromatičan ili heterocikličan psten odabran od fenil, pirolidinil, pirolidinilona, imidazolila, piridinil, piridinil oksida, piperidinila, piperazinila, piridazinila, morfolinila i indolinilon grupa, i po izboru supstituisan sa jedan, dva ili tri ista ili različita supstituenta odabrana od halogena, C1-C4 alkil grupa, C1-C4 alkoksi, trifluorometil, nitro, N(R)2, -CH2-N(R)2, -O-(CH2)n-N(R)2, hidroksil, cijano, C2-C3 cijanoalkil, 5-okso-1,2,4-oksadiazolidinil i grupe formule- X-[C(R2)]p-CORa,- X je jednostruka veza, atom kiselinika, -O-CH2-, atom sumpora, -NR- grupa ili 1,1-ciklopropilen grupa,- Ra je OR ili N(R)2,- R je atom vodonika ili C1-C4 alkil grupa, i- p je 0, 1, 2, 3 ili 4; iii) farmaceutski prihvatljivih soli jedinjenja formule (I).Prijava sadrži još 11 patentnih zahteva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0505432A FR2886293B1 (fr) | 2005-05-30 | 2005-05-30 | Nouveaux composes de l'indoline |
| PCT/FR2006/050487 WO2007000550A2 (fr) | 2005-05-30 | 2006-05-29 | Composes de l' indoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS50969B true RS50969B (sr) | 2010-10-31 |
Family
ID=35501068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2009/0244A RS50969B (sr) | 2005-05-30 | 2006-05-29 | Jedinjenja indolina |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7465811B2 (sr) |
| EP (1) | EP1885695B8 (sr) |
| JP (1) | JP2008545736A (sr) |
| KR (1) | KR20080021609A (sr) |
| CN (2) | CN101184731A (sr) |
| AT (1) | ATE423768T1 (sr) |
| AU (1) | AU2006263745B2 (sr) |
| BR (1) | BRPI0610064A2 (sr) |
| CA (1) | CA2611128A1 (sr) |
| CY (1) | CY1109043T1 (sr) |
| DE (1) | DE602006005356D1 (sr) |
| DK (1) | DK1885695T3 (sr) |
| EA (1) | EA012971B1 (sr) |
| ES (1) | ES2322620T3 (sr) |
| FR (1) | FR2886293B1 (sr) |
| HK (1) | HK1112235A1 (sr) |
| HR (1) | HRP20090243T1 (sr) |
| IL (1) | IL187413A (sr) |
| MA (1) | MA29494B1 (sr) |
| MX (1) | MX2007015070A (sr) |
| NO (1) | NO20075841L (sr) |
| PL (1) | PL1885695T3 (sr) |
| PT (1) | PT1885695E (sr) |
| RS (1) | RS50969B (sr) |
| SI (1) | SI1885695T1 (sr) |
| TN (1) | TNSN07448A1 (sr) |
| UA (1) | UA92013C2 (sr) |
| WO (1) | WO2007000550A2 (sr) |
| ZA (1) | ZA200710258B (sr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2869904B1 (fr) * | 2004-05-07 | 2006-07-28 | Fournier S A Sa Lab | Modulateurs des recepteurs lxr |
| GB0526257D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| AR071375A1 (es) * | 2008-04-22 | 2010-06-16 | Solvay Pharm Gmbh | Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto |
| TWI748194B (zh) * | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
| CN114773190A (zh) * | 2022-04-20 | 2022-07-22 | 江西天宇化工有限公司 | 一种制备2,4-二氯苯氧乙酸异辛酯的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316503B1 (en) * | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| US6855708B2 (en) * | 2001-03-20 | 2005-02-15 | Merck & Co., Inc. | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors |
| TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| DE10229777A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| FR2869904B1 (fr) * | 2004-05-07 | 2006-07-28 | Fournier S A Sa Lab | Modulateurs des recepteurs lxr |
-
2005
- 2005-05-30 FR FR0505432A patent/FR2886293B1/fr not_active Expired - Fee Related
-
2006
- 2006-05-29 PL PL06794466T patent/PL1885695T3/pl unknown
- 2006-05-29 ZA ZA200710258A patent/ZA200710258B/xx unknown
- 2006-05-29 SI SI200630288T patent/SI1885695T1/sl unknown
- 2006-05-29 PT PT06794466T patent/PT1885695E/pt unknown
- 2006-05-29 RS RSP-2009/0244A patent/RS50969B/sr unknown
- 2006-05-29 KR KR1020077027315A patent/KR20080021609A/ko not_active Application Discontinuation
- 2006-05-29 UA UAA200713357A patent/UA92013C2/ru unknown
- 2006-05-29 JP JP2008514163A patent/JP2008545736A/ja active Pending
- 2006-05-29 EP EP06794466A patent/EP1885695B8/fr active Active
- 2006-05-29 WO PCT/FR2006/050487 patent/WO2007000550A2/fr active Application Filing
- 2006-05-29 MX MX2007015070A patent/MX2007015070A/es active IP Right Grant
- 2006-05-29 DE DE602006005356T patent/DE602006005356D1/de active Active
- 2006-05-29 BR BRPI0610064-3A patent/BRPI0610064A2/pt not_active IP Right Cessation
- 2006-05-29 CN CNA2006800188334A patent/CN101184731A/zh active Pending
- 2006-05-29 CN CN2012101789237A patent/CN102746214A/zh active Pending
- 2006-05-29 AT AT06794466T patent/ATE423768T1/de active
- 2006-05-29 EA EA200702324A patent/EA012971B1/ru not_active IP Right Cessation
- 2006-05-29 DK DK06794466T patent/DK1885695T3/da active
- 2006-05-29 AU AU2006263745A patent/AU2006263745B2/en not_active Ceased
- 2006-05-29 CA CA002611128A patent/CA2611128A1/fr not_active Abandoned
- 2006-05-29 ES ES06794466T patent/ES2322620T3/es active Active
-
2007
- 2007-11-14 NO NO20075841A patent/NO20075841L/no not_active Application Discontinuation
- 2007-11-15 IL IL187413A patent/IL187413A/en not_active IP Right Cessation
- 2007-11-29 TN TNP2007000448A patent/TNSN07448A1/fr unknown
- 2007-11-29 MA MA30435A patent/MA29494B1/fr unknown
- 2007-11-30 US US11/947,998 patent/US7465811B2/en active Active
-
2008
- 2008-07-04 HK HK08107399.4A patent/HK1112235A1/xx not_active IP Right Cessation
-
2009
- 2009-04-23 CY CY20091100454T patent/CY1109043T1/el unknown
- 2009-04-24 HR HR20090243T patent/HRP20090243T1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090243T1 (en) | Indoline compounds | |
| NO20056196L (no) | Makrocykliske kinazolinderivater som antiproliferative midler | |
| NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
| WO2005080384A3 (en) | Benzimidazole derivative and use as aii receptor antagonist | |
| HK1096663A1 (en) | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | |
| PL1672017T3 (pl) | Mieszaniny kauczukowe | |
| HUP0302922A2 (hu) | Sejtburjánzást gátló hatású imidazolo-5-il-2-anilino-pirimidinek és ezeket tartalmazó gyógyszerkészítmények | |
| RU2008123388A (ru) | Соединения и композиции в качестве модуляторов lxr | |
| DE502005001916D1 (de) | Substituierte oxindol-derivate und diese enthaltende arzneimittel | |
| MXPA05006907A (es) | Compuestos diazoicos cationicos, composiciones que los contienen como colorante directo, procedimiento de coloracion de fibras queratinicas y dispositivo. | |
| EP1829863A4 (en) | ARYLALCANOIC ACID DERIVATIVE | |
| MXPA02012001A (es) | Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas receptores de neurocinina. | |
| PL1742957T3 (pl) | Sposób otrzymywania telitromycyny | |
| NO20054135L (no) | Kipolinon/benzoksazin derivater og anvendelser derav | |
| MX2010009959A (es) | Compuestos y metodo para reducir el acido urico. | |
| ID30498A (id) | Senyawa-senyawa turunan amina | |
| TW200745033A (en) | Oxindole derivative as feeding control agent | |
| EP1798227A4 (en) | SEROTONIN 5-HT3 RECEPTOR AGONIST | |
| NO984761L (no) | Aminoisokinoliner og aminotienopyridinderivater og deres anvendelse som antiinflammatoriske midler | |
| SE0201194D0 (sv) | New compounds | |
| ATE502936T1 (de) | 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten | |
| JP2011510072A5 (sr) | ||
| JP2010518016A5 (sr) | ||
| WO2009027626A3 (en) | Improvements in or relating to organic compounds | |
| NO20054794L (no) | 7 ([1, 4] dioksan-2-yl)-benzotiazolderivater som adenosinreseptorligander |